Literature DB >> 21615545

Recurrent vulvovaginal candidosis: focus on the vulva.

Florian C Beikert1, Minh T Le, Angela Koeninger, Kristin Technau, Andreas Clad.   

Abstract

Recurrent vulvovaginal candidosis is a frequent disease with a serious impact on women's quality of life. Mostly, recurrences are caused by identical Candida strains suggesting C. albicans persistence in the female anogenital area. Objectives of the presented work were to identify the site of C. albicans persistence, to determine clinical symptoms and signs related to C. albicans positive vulvar cultures and to introduce a new therapeutic approach in women with RVVC. Women with an acute, culture-confirmed episode of RVVC at time of visit were included in this prospective case series. Swabs were obtained from both vagina and inter-labial sulcus. Women received a combined 20-day regimen of 100 mg oral fluconazole and ciclopiroxolamin cream topically. Follow-up visits were at 3, 6, 9 and 12 months. Of 139 women, 105 (76%) had at least one C. albicans positive culture from the external vulva. Vulvar positive cultures correlated with pruritus (OR 5.4; P < 0.001), vulvar edema (OR 3.8; P = 0.03) and fissures (OR 2.4; P = 0.03). Recurrence rates were 27%, 33% and 34% (at 6, 9, 12 months, respectively). The external vulva appears to represent a site of C. albicans persistence and source of endogenous re-infection in patients with RVVC. The combined treatment compared favorably with published fluconazole maintenance regimens.
© 2011 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615545     DOI: 10.1111/j.1439-0507.2011.02030.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  7 in total

1.  Three-Day Combination Treatment for Vulvovaginal Candidosis with 200 mg Clotrimazol Vaginal Suppositories and Clotrimazol Cream for the Vulva is Significantly Better than Treatment with Vaginal Suppositories Alone - an Earlier, Multi-Centre, Placebo-Controlled Double Blind Study.

Authors:  W Mendling; R Schlegelmilch
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-04       Impact factor: 2.915

2.  Lactobacillus acidophilus, L. plantarum, L. rhamnosus, and L. reuteri Cell-Free Supernatants Inhibit Candida parapsilosis Pathogenic Potential upon Infection of Vaginal Epithelial Cells Monolayer and in a Transwell Coculture System In Vitro.

Authors:  Luca Spaggiari; Arianna Sala; Andrea Ardizzoni; Francesco De Seta; Dhirendra Kumar Singh; Attila Gacser; Elisabetta Blasi; Eva Pericolini
Journal:  Microbiol Spectr       Date:  2022-05-02

3.  Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Authors:  Sujit D Rathod; Patricia A Buffler
Journal:  BMC Womens Health       Date:  2014-03-10       Impact factor: 2.809

Review 4.  Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development.

Authors:  Małgorzata Bondaryk; Wiesław Kurzątkowski; Monika Staniszewska
Journal:  Postepy Dermatol Alergol       Date:  2013-10-30       Impact factor: 1.837

Review 5.  Probiotics in the Prevention and Treatment of Postmenopausal Vaginal Infections: Review Article.

Authors:  Jun-Mo Kim; Yoo Jin Park
Journal:  J Menopausal Med       Date:  2017-12-29

6.  Prevalence and Antifungal Susceptibility Profile of Clinically Relevant Candida Species in Postmenopausal Women with Diabetes.

Authors:  Sarah Al Halteet; Ahmed Abdel-Hadi; Mohamed Hassan; Mohamed Awad
Journal:  Biomed Res Int       Date:  2020-11-26       Impact factor: 3.411

7.  Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates.

Authors:  Tchana Martinez Brandolt; Gabriel Baracy Klafke; Carla Vitola Gonçalves; Laura Riffel Bitencourt; Ana Maria Barral de Martinez; Josiara Furtado Mendes; Mário Carlos Araújo Meireles; Melissa Orzechowski Xavier
Journal:  Braz J Microbiol       Date:  2016-10-04       Impact factor: 2.476

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.